Armoiry X, et al. - This systematic review was performed to examine trials evaluating the short- and long-term clinical effectiveness of the use of beta-interferon (IFN-β) or glatiramer acetate (GA) acetate for people with the clinically isolated syndrome (CIS). Compared to placebo, IFN-β and GA were discovered to delay the time to clinically definite multiple sclerosis.